24/7 Market News Snapshot 15 October, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)

October 15, 2025

DENVER, Colo., 15 October, 2025 (www.247marketnews.com) – (Nasdaq:SPRC) are discussed in this article.
SciSparc Ltd. (Nasdaq:SPRC) is experiencing a notable upswing, trading at $3.805, reflecting a 10.29% increase from the previous close of $3.450 in pre-market activity. This rise can be attributed to heightened investor enthusiasm, evidenced by a sizeable trading volume of 521.38K shares. As the stock shows signs of bullish momentum, crucial resistance levels are set at $4.00, while support is noted at $3.50. Investors are advised to closely monitor these price points for potential breakout scenarios.

In tandem with its market performance, SciSparc has secured a transformative asset and share purchase agreement with Miza III Ventures Inc. (TSXV: MIZA.P), finalized on October 9, 2025. This agreement encompasses the transfer of SciSparc’s advanced clinical-stage pharmaceutical portfolio and a controlling equity stake in SciSparc Nutraceuticals Inc. with an estimated asset value of approximately US$11.6 million.

As part of this deal, SciSparc will receive 63.3 million common shares of Miza, with opportunities for additional shares contingent upon achieving specified milestones. Upon completion of this transaction, slated for around October 22, 2025, SciSparc is expected to hold 75% to 84% of Miza, which will subsequently be rebranded as “NeuroThera Labs Inc.” This maneuver positions Miza to operate within both the pharmaceutical and nutraceutical sectors, enhancing its market reach.

Moreover, SciSparc plans to extend up to CAD 1,000,000 (approximately US$716 thousand) in capital through an unsecured convertible note to bolster Miza’s operations. This note is convertible into common shares at a price of CAD 0.25 per share, presenting a significant investment opportunity.

With a steadfast commitment to developing cannabinoid-based pharmaceuticals targeting conditions such as Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder, SciSparc aims to create substantial shareholder value while advancing healthcare solutions that enhance quality of life. Further updates will be shared as developments unfold.

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.